Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020
1234
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
News Every Day |

Drugmakers refuse to attend White House meeting after Trump issues executive orders on costs


A White House meeting with top pharmaceutical executives that President Donald Trump promised for Tuesday is off, five industry sources familiar with discussions told POLITICO. Three said the drug-pricing discussion was canceled because the major drug lobbies, reeling from Friday’s cluster of executive orders on the topic, refused to send any members.

Drugmakers and Trump were slated to discuss an executive order, signed Friday but not yet released, that would order health officials to release a plan linking Medicare payments for certain medicines to lower costs paid abroad. The provision, known as a most-favored-nations rule, has been lambasted by the drug industry and some patient groups that say it would curb innovation and reduce drug access.

Trump said Friday that drugmakers would have a month to present a better option to the rule.

The drug lobbies PhRMA and BIO were reluctant to send representatives from their member companies — many of them multibillion-dollar manufacturers of the world’s best-selling medicines and vaccines — after conflicting reports last week about whether the White House would include the rule and little information to date about what the new rule would look like, three people familiar with the discussions said.

Several pharmaceutical companies believed that the most-favored nations rule had been dropped ahead of the Friday afternoon announcement. The hours before Trump’s drug pricing event were a “chaotic” back-and-forth that even left some of his health officials surprised, sources told POLITICO Friday.

BIO, the lobby representing many small biotechnology companies developing therapies, has said that the most-favored-nations rule would hit its members the hardest. Many make the type of physician-administered medicines, such as expensive cancer and arthritis infusions, that would be affected.

"There are discussions taking place to determine the best way to work with the administration on this issue over the coming weeks," said an industry source.

"The White House has been more than accommodating in attempts to schedule this meeting," a White House official said on background.

A PhRMA spokesperson painted the White House talks as a distraction. "The president’s plan to import policies from socialized health care systems abroad is disrupting our work [on Covid-19 therapies] and diverting our focus away from those life-saving efforts," the spokesperson said. "We remain willing to discuss ways to lower costs for patients at the pharmacy counter. However, we remain steadfastly opposed to policies that would allow foreign governments to set prices for medicines in the United States."

Inside Health Policy first reported that the meeting was canceled. The White House did not immediately respond to request for comment.

The favored nations rule has rankled conservative groups along with the industry and patient organizations. The president on Friday left the door open for alternative options, saying that if drugmakers can present a better plan “we may not need to implement the fourth executive order, a very tough order.”

Susannah Luthi and David Lim contributed to this report.



Read also

Iraqi-born Hala Jarbou appointed as US federal judge

Coronation Street’s Tisha Merry says she’ll marry Alan Halsall and have kids but reveals she didn’t fancy him at first

Man who won SCOTUS flag-burning case visits Portland protests



News, articles, comments, with a minute-by-minute update, now on Today24.pro




Today24.pro — latest news 24/7. You can add your news instantly now — here